Insulet Corp.
PODD
Rangering i aksjer
#2087
Insulet Corporation develops, manufactures, and sells insulin delivery systems... Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Aksjekurs
$142.84
Markedsverdi
$9.91B
Endring (1 dag)
0.62%
Endring (1 år)
-56.30%
Land
US
Handel Insulet Corp. (PODD)
Kategori
Healthcare
Inntekter for Insulet Corp. (PODD)
Inntekter i Jun 2026 TTM: $3.05B
Ifølge de nyeste økonomiske rapportene til Insulet Corp. er selskapets nåværende inntekter (TTM) $3.05B. I 2023 hadde selskapet inntekter på $1.70B en økning sammenlignet med inntektene i 2022, som var $1.31B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Insulet Corp. fra 2002 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $3.05B | 47.40% |
| 2024 | $2.07B | 22.07% |
| 2023 | $1.70B | 30.02% |
| 2022 | $1.31B | 18.79% |
| 2021 | $1.10B | 21.49% |
| 2020 | $904.40M | 22.51% |
| 2019 | $738.20M | 30.93% |
| 2018 | $563.82M | 21.57% |
| 2017 | $463.77M | 26.37% |
| 2016 | $366.99M | 39.07% |
| 2015 | $263.89M | -8.60% |
| 2014 | $288.72M | 16.85% |
| 2013 | $247.08M | 16.90% |
| 2012 | $211.37M | 38.83% |
| 2011 | $152.26M | 57.02% |
| 2010 | $96.97M | 46.85% |
| 2009 | $66.03M | 83.12% |
| 2008 | $36.06M | 169.66% |
| 2007 | $13.37M | 265.06% |
| 2006 | $3.66M | 7,226.00% |
| 2005 | $50.00K | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $46.59B | 1,425.63% |
US
|
|
| $35.48B | 1,062.08% |
IE
|
|
| $25.84B | 746.14% |
US
|
|
| $21.00B | 587.60% |
US
|
|
| - | - |
DE
|
